Macrophage migration inhibitory factor

Expert Opinion on Therapeutic Targets

Volumn 7, Issue 2, 2003, Pages 153-164

  Lolis, Elias ^a   Bucala, Richard ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acetaminophen; Arthritis; Bioterrorism; Cytokine; Isomerase; Isoxazolone; Macrophage migration inhibitory factor (MIF); NAPQI; Shock

Indexed keywords

3 (4 HYDROXYPHENYL) 4,5 DIHYDRO 5 ISOXAZOLE ACETIC ACID METHYL ESTER; 3 (4 HYDROXYPHENYL) 4,5 DIHYDRO 5 ISOXAZOLE ACETIC ACID METHYL ESTER DERIVATIVE; BINDING PROTEIN; CYTOKINE; DRUG METABOLITE; ISO 1; ISOXAZOLINE DERIVATIVE; JUN ACTIVATION DOMAIN BINDING PROTEIN 1; MACROPHAGE MIGRATION INHIBITION FACTOR; MACROPHAGE MIGRATION INHIBITION FACTOR ANTIBODY; MACROPHAGE MIGRATION INHIBITION FACTOR INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; N ACETYL 3 HYDROXY 4 BENZOQUINONE IMINE; N ACETYL 4 BENZOQUINONE IMINE; NEUTRALIZING ANTIBODY; PARACETAMOL; PROTEIN C JUN; PROTEIN INHIBITOR; PROTEIN P53; RECEPTOR; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DESIGN; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME STRUCTURE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; REGULATORY MECHANISM; REVIEW;

ANIMALS; AUTOIMMUNE DISEASES; CLINICAL TRIALS; CYTOKINES; DRUG DESIGN; GLUCOCORTICOIDS; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNITY, NATURAL; IMMUNOLOGIC FACTORS; INFECTION; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASES; MICE; MODELS, MOLECULAR; NITRIC OXIDE; PEPTIDE HYDROLASES; PROTEIN CONFORMATION; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TOLL-LIKE RECEPTOR 4; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037396877     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.7.2.153     Document Type: Review

References (90)

1. LINDE-ZWIRBLE WT, ANGUS DC, CARCILLO J, LIDICKER J, CLERMONT G, PINSKY MR: Age-specific incidence and outcome of sepsis in the US. Crit. Care Med. (1999) 27:A33.
2. FRANZ, DR, JAHRLING PB, FRIEDLANDER A et al.: Clinical recognition and management of patients exposed to biological warfare agents. JAMA (1997) 278:399-411.
3. JANEWAY CA, TRAVERS P, WALPORT M, SHLOMCHIK M: Innate Immunity. In: Immunobiology. Garland, New York (2001):35-91.
4. GEORGE M, VAUGHN JH: In vitro cell migration as a model for delayed hypersensitivity. Proc. Soc. Exp. Biol. Med. (1962) 111:514-521.
5. DAVID J: Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc. Natl. Acad. Sci. USA (1966) 56:72-77.
6. BLOOM BR, BENNETT B: Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science (1966) 153:80-82.
7. WEISER WY, TEMPLE PA, WITEK-GIANNOTTI JS, REMOLD HG, CLARK SC, DAVID JR: Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc. Natl. Acad. Sci. USA (1989) 86:7522-7526.
8. BERNHAGEN J, CALANDRA T, MITCHELL RA et al.: MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature (1993) 365:756-759.
9. BERNHAGEN J, MITCHELL RA, CALANDRA T, VOELTER W, CERAMI A, BUCALA R: Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry (1994) 33:14144-14155.
10. WAEBER G, CALANDRA T, RODUIT R et al.: Insulin secretion is regulated by the glucose-dependent production of islet β cell macrophage migration inhibitory factor. Proc. Natl. Acad. Sci. USA (1997) 94:4782-4787.
11. MEINHARDT A, BACHER M, MCFARLANE JR et al.: Macrophage migration inhibitory factor production by Leydig cells: evidence for a role in the regulation of testicular function. Endocrinology (1996) 137:5090-5095.
12. BACHER M, MEINHARDT A, LAN HY et al.: MIF expression in the rat brain: implications for neuronal function. Mol. Med. (1998) 4:217-230.
13. CALANDRA T, BERNHAGEN J, METZ CN et al.: MIF as a glucocorticoid-induced modulator of cytokine production. Nature (1995) 377:68-71.
14. BOUMPAS DT, WILDER RL: Corticosteroids. In: Arthritis and Allied Conditions. Koopman WJ (Ed.), Lippincott Williams & Wilkins, Philadelphia (2001):827-847.
15. BEISHUIZEN A, THIJS LG, HAANEN C et al.: Macrophage migration inhibitory factor and hypothalamic-pituitary-adrenal function during critical illness. J. Clin. Endocrinol. Metab. (2001) 86:2811-2816.
16. PETROVSKY N, SOCHA L, SILVA D, GROSSMAN AB, METZ C, BUCALA R. Macrophage migration inhibitory factor (MIF) exhibits a pronounced circadian rhythm relevant to its role as a glucocorticoid counter-regulator (2002). In Press.
17. BACHER M, METZ CN, CALANDRA T et al.: An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc. Natl. Acad. Sci. USA (1996) 93:7849-7854.
18. DONNELLY SC, HASLETT C, REID PT et al.: Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat. Med. (1997) 3:320-323.
19. DAUN JM, CANNON JG: Macrophage migration inhibitory factor antagonizes hydrocortisone-induced increases in cytosolic IκBα. Am. J. Physiol. (2000) 279:R1043-R1049.
20. LEECH M, METZ C, BUCALA R, MORAND EF: Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheum. (2000) 43:827-833.
21. WANG L, DAS H, KAMATH A, LI L, BUKOWSKI JF: Human 2V δ 2T cells augment MIF secretion and counteract the inhibitory effect of glucocorticoids on IL-1β and TNF-α production. J. Immunol. (2002) 168:4889-4896.
22. BUCALA R: MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. FASEB J. (1996) 10:1607-1613.
23. CALANDRA T, BERNHAGEN J, MITCHELL RA, BUCALA R: The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med. (1994) 179:1895-1902.
24. BOZZA M, SATOSKAR AR, LIN G et al.: Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J. Exp. Med. (1999) 189:341-346.
25. ONADERA S, KANEDA K, MIZUE YKM, FUJINAGA. M, NISHIHIRA J: Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. J. Biol. Chem. (2000) 275:444-450.
26. ONADERA S, NISHIHIRA J, IWABUCHI K et al.: Macrophage migration inhibitory factor up-regulates matrix mctalloproteinase-9 and -13 in rat osteoblasts. Relevance to intracellular signaling pathways. J. Biol. Chem. (2002) 277:7865-7874.
27. MITCHELL RA, LIAO H, CHESNEY J et al.: Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc. Natl. Acad. Sci. USA (2002) 99:345-350.
28. SAMPEY AV, HALL PH, MITCHELL RA, METZ CN, MORAND EF: Regulation of synoviocytc phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor. Arthritis Rheum. (2001) 44:1273-1280.
29. JUTTNER S, BERNHAGEN J, METZ CN, ROLLINGHOFF M, BUCALA R, GESSNER A: Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF-α. J. Immunol. (1998) 161:2383-2390.
30. XU D, MCSORLEY MJ, TETLEY L et al.: Protective effect on Leishmania major infection of MIF, TNF-α, and IFN-γ administered orally via attenuated Salmonella typhimurium. J. Immunol. (1998) 160:1285-1289.
31. SATOSKAR A, BOZZA M, RODRIGUEZ SOSA M, LIN G, DAVID JR. Migration inhibitory factor gene-deficient mice are susceptible to cutaneous Leishmania major infection. Infect. Immun. (2001) 69:906-911.
32. MITCHELL RA, METZ CN, PENG TBR. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). J. Biol. Chem. (1999) 274:18100-18106.
33. BENIGNI F, ATSUMI T, CALANDRA T et al.: The proinflammatory mediator macrophage migration inhibitory factor (MIF) induces glucose catabolism in muscle. J. Clin. Invest. (2000) 106:1291-1300.
34. MARSHALL CJ: Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell (1995) 179-185.
35. HOWE AK, JULIANO RL: Distinct mechanisms mediate the initial and sustained phases of integrin-mediated activation of the Raf/MEK/mitogen-activated protein kinase cascade. J. Biol. Chem. (1998) 273:27268-27274.
36. MURAKAMI M, NAKATANI Y, ATSUMI G, INOUE K, KUDO I: Regulatory functions of phospholipase A2. Crit. Rev. Immunol. (1997) 17:225-283.
37. SWANTEK JL, COBB MH, GEPPERT TD: Jun N-terminal kinase/stress activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor-α (TNF-α) translation: glucocorticoids inhibit TNF-α translation by blocking JNK/SAPK. Mol. Cell. Biol. (1997) 17:6274-6282.
38. HONMA N, KOSECKI H, AKASAKA T et al.: Deficiency of the MIF gene has no significant effect on endotoxaemia. Immunology (2000) 100:84-90.
39. ROGER T, DAVID J, GLAUSER. MP, CALANDRA T: MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature (2001) 414:920-924.
40. CALANDRA T, SPIEGEL LA, METZ CN, BUCALA R: Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. Proc. Natl. Acad. Sci. USA (1998) 95:11383-11388.
41. HUDSON JD, SHOAIBI MA, MAESTRO R, CARNERO A, HANNON GJ, BEACH DH: A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. (1999) 190:1375-1382.
42. MAHIDHARA R, BILLIAR TR: Apoptosis in sepsis. Crit. Care Med. (2000) 28:N105-N113.
43. ALBINA JE, CUI S, MATEO RB, REICHNER JS: Nitric oxide-mediated apoptosis in murine peritoneal macrophages. J. Immunol. (1993) 150:5080-5085.
44. KLEEMANN R, HAUSSER A, GEIGER G et al.: Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature (2000) 408:211-216.
45. SUZUKI M, SUGIMOTO H, NAKAGAWA A, TENAKA I, NISHIHIRA J, SAKAI M: Crystal structure of the macrophage migration inhibitory factor from rat liver. Nature Struct. Biol. (1996) 3:259-266.
46. SUN HW, BERNHAGEN J, BUCALA R, LOLIS E: Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc. Natl. Acad. Sci. USA (1996) 93:5191-5196.
47. ROSENGREN E, BUCALA R, AMAN P et al.: The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol. Med. (1996) 2:143-149.
48. SUBRAMANYA HS, ROPER DI, DAUTER Z et al.: Enzymatic ketonization of 2-hydroxymuconate: specificity and mechanism investigated by the crystal structures of two isomerases. Biochemistry (1996) 35:792-802.
49. MATSUNAGA J, SINHA D, PANNELL L et al.: Enzyme activity of macrophage migration inhibitory factor toward oxidized catecholamines. J. Biol. Chem. (1999) 274:3268-3271.
50. ROSENGREN E, AMAN P, THELIN S et al.: The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase. FEBS Lett. (1997) 417:85-88.
51. TAYLOR AB, JOHNSON WHJ, CZERWINSKI RM et al.: Crystal structure of macrophage migration inhibitory factor complexcd with (E)-2-fluoro-p-hydroxycinnamate at 1.8 A resolution: implications for enzymatic catalysis and inhibition. Biochemistry (1999) 38:7444-7452.
52. SWOPE M, SUN HW, BLAKE PR, LOLIS E: Direct link between cytokine activity and a catalytic site for macrophage migration inhibitory factor. EMBO J. (1998) 17:3534-3541.
53. STIVERS JT, ABEYGUNAWARDANA C, MILDVAN AS, HAJIPOUR G, WHITMAN CP: 4-Oxalocrotonate tautomerase: pH dependence of catalysis and pKa values of active site residues. Biochemistry (1996) 35:814-823.
54. BENDRAT K, AL-ABED Y, CALLAWAY DJ et al.: Biochemical and mutational investigations of the enzymatic activity of macrophage migration inhibitory factor. Biochemistry (1997) 36:15356-15362.
55. HERMANOWSKI-VOSATKA A, MUNDT SS, AYALA JM et al.: Enzymatically inactive macrophage migration inhibitory factor inhibits monocyte chemotaxis and random migration. Biochemistry (1999) 38:12841-12849.
56. LUBETSKY JB, SWOPE M, DEALWIS C, BLAKE P, LOLIS E: Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity. Biochemistry (1999) 38:7346-7354.
57. LUBETSKY JB, DIOS A, HAN J et al.: The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J. Biol. Chem. (2002) 277:24976-24982.
58. KLEEMANN R, KAPURNIOTU A, FRANK RW et al.: Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J. Mol. Biol. (1998) 280:85-102.
59. KLEEMANN R, MISCHKE R, KAPURNIOTU A, BRUNNER H, BERNHAGEN J: Specific reduction of insulin disulfides by macrophage migration inhibitory factor (MIF) with glutathione and dihydrolipoamide: potential role in cellular redox processes. FEBS Lett. (1998) 430:191-196.
60. KLEEMANN R, KAPURNIOTU A, MISCHKE R, HELD J, BERNHAGEN J: Characterization of catalytic centre mutants of macrophage migration inhibitory factor (MIF) and comparison to Cys81 Ser MIF. Eur. J. Biochem. (1999) 261:753-766.
61. JUNG H, KIM T, CHAE HZ, KIM KL, HA H: Regulation of macrophage migration inhibitory factor and thiol-specific antioxidant protein PAG by direct interaction. J. Biol. Chem. (2001) 276:15504-15510.
62. FELDMANN M, MAINI RN: Anti-TNF-α therapy of rheumatoid arthritis: what have we learned? Ann. Rev. Immunol. (2001) 19:163-196.
63. BAUGH JA, BUCALA R: Mechanisms for modulating TNF-α in immune and inflammatory disease. Curr. Opin. Drug Discov. Dev. (2001) 4:635-650.
64. VINCENT JL, MORENO R, TAKALA J: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. (1996) 22:707-710.
65. YOUNG LS: Sepsis Syndrome. In: Principles and Practice of Infectious Diseases. Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, New York (2000):806-820.
66. ABRAHAM E: Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med. (1999) 25:556-566.
67. CALANDRA T, ECHTENACHER B, ROY DL et al.: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med. (2000) 6:164-169.
68. SUZUKI M, SUGIMOTO H, TANAKA I, NISHIHIRA J: Substrate specificity for isomerase activity of macrophage migration inhibitory factor and its inhibition by indole derivatives. J. Biochem. (1997) 122:1040-1045.
69. ZHANG X, BUCALA R: Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity by dopachrome analogs. Bioorg. Med. Chem. Lett. (1999) 9:3193-3198.
70. STAMPS SL, FITZGERALD MC, WHITMAN CP: Characterization of the role of the amino-terminal proline in the enzymatic activity catalyzed by macrophage migration inhibitory factor. Biochemistry (1998) 37:10195-10202.
71. SENTER P, AL-ABED Y, METZ CN et al.: Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc. Natl. Acad. Sci. USA (2002) 99:144-149.
72. RAFFA RB, CODD EE: Lack of binding of acetaminophen to 5-HT receptor or uptake sites (or eleven other binding/uptake assays). Life Sci. (1996) 59:37-40.
73. DENKINGER CM, DENKINGER M, KORT JJ, METZ C, FORSTHUBER TG: In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system. J. Immunol. (2003) 170:1274-1282.
74. DIOS A, MITCHELL RA, ALJABARI B et al.: Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. J. Med. Chem. (2002) 45:2410-2416.
75. MIKULOWSKA A, METZ CN, BUCALA R, HOLMDAHL R: Macrophage migration inhibitory factor is involved in the pathogenesis of collagen Type II-induced arthritis in mice. J. Immunol. (1997) 158:5514-5517.
76. LEECH M, METZ C, SANTOS L et al.: Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum. (1998) 41:910-917.
77. LAN HY, BACHER M, YANG N et al.: The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J. Exp. Med. (1997) 185:1455-1465.
78. CHESNEY J, METZ C, BACHER M, PENG T, MEINHARDT A, BUCALA R: An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol. Med. (1999) 5:181-191.
79. OGAWA H, NISHIHIRA J, SATO Y et al.: An antibody for macrophage migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis. Cytokine (2000) 12:309-314.
80. BERNHAGEN J, BACHER M, CALANDRA T et al.: An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J. Exp. Med. (1996) 183:277-282.
81. LAN HY, MU W, YANG N et al.: De novo renal expression of macrophage migration inhibitory factor during the development of rat crescentic glomerulonephritis. Am. J. Pathol. (1996) 149:1119-1127.
82. BROWN FG, NIKOLIC-PATERSON DJ, METZ C, BUCALA R, ATKINS RC, LAN HY: Up-regulation of macrophage migration inhibitory factor (MIF) in acute renal allograft rejection in the rat. Clin. Exp. Immunol. (1999) 118:329-336.
83. HOU G, VALUJSKIKH A, BAYER J, STAVITSKY AB, METZ C, HEEGER PS: In vivo blockade of macrophage migration inhibitory factor prevents skin graft destruction after indirect allorecognition. Transplantation (2001) 72:1890-1897.
84. MEYER-SIEGLER K, HUDSON PB: Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology (1996) 48:448-452.
85. DE JONG YP, ABADIA-MOLINA AC, SATOSKAR AR et al.: Development of chronic colitis is dependent on the cytokine MIF. Nat. Immunol. (2001) 2:1061-1066.
86. MARTINEY JA, SHERRY B, METZ CN et al.: Macrophage migration inhibitory factor (MIF) release by macrophages after ingestion of Plasmodium chabaudi-infected erythrocytes: possible role in the pathogenesis of malaria anemia. Infect. Immun. (2000) 68:2259-2267.
87. KITAICHI N, KOTAKE S, MIZUE Y et al.: High-dose corticosteroid administration induces increase of serum macrophage migration inhibitory factor in patients with Vogt-Koyanagi-Harada's disease. Microbiol. Inmunol. (2000) 44:1075-1077.
88. TAGUCHI C, SUGITA S, TAGAWA Y, NISHIHIRA J, MOCHIZUKI M: Macrophage migration inhibitory factor in ocular fluids of patients with uveitis. Br. J. Ophthalmol. (2001) 85:1367-1371.
89. LIN SG, YU XY, CHEN Y-X et al.: De novo expression of macrophage migration inhibitory in atherogenesis in rabbits. Circ. Res. (2000) 87:1202-1208.
90. BURGER-KENTISCHERA, GOEBEL H, SEILER R et al.: Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation (2002) 105:1561-1566.